India to Gambia: Acetylsalicylic Export Trade Route

To import Acetylsalicylic acid formulations into The Gambia, the following approvals and registrations are required:

1. Product Registration: All pharmaceutical products must be registered with the MCA. Applications should be submitted in the Common Technical Document (CTD) format, both in hard and soft copies. The application must include comprehensive data on the product's quality, safety, and efficacy. The MCA charges a non-refundable processing fee for each import permit, payable upon submission. Specific fee amounts are detailed in the MCA's fee schedule. (mca.gm)

2. Import Permit: An import permit is mandatory for each shipment. The importer must submit an import declaration form along with supporting documents, including the invoice, bill of lading or air waybill, certificate of origin, packing list, and any required licenses or certificates. A valid Tax Identification Number (TIN) is also necessary.

3. Pre-shipment Inspection and Testing: Effective July 1, 2023, the MCA requires pre-shipment document verification, physical inspection, quality control testing, and the issuance of a Clean Report of Inspection and Analysis (CRIA) for all pharmaceutical products imported from India. Quntrol Laboratories Private Limited has been appointed to conduct these inspections. Shipments arriving with a bill of lading dated on or after July 1, 2023, must provide a CRIA for customs clearance.

4. Good Manufacturing Practice (GMP) Compliance: Indian manufacturing facilities producing Acetylsalicylic acid formulations must comply with WHO-GMP standards. The MCA may require GMP certificates and conduct inspections to verify compliance. Specific timelines for approval and inspection requirements are outlined in the MCA's guidelines. (mca.gm)

Indian exporters of Acetylsalicylic acid formulations must adhere to the following quality and GMP standards to supply products to The Gambia:

1. WHO-GMP Certification: Manufacturing facilities must hold valid WHO-GMP certificates, ensuring that products meet international quality standards. The MCA recognizes these certifications as part of the product registration process. (mca.gm)

2. Pre-shipment Inspection: As of July 1, 2023, all shipments from India require pre-shipment inspection and testing. This process includes document verification, physical inspection, and quality control testing, culminating in the issuance of a CRIA. This measure aims to prevent substandard and counterfeit medicines from entering The Gambia.

3. Regulatory Actions: There have been no publicly reported regulatory actions by the MCA against Indian pharmaceutical companies exporting to The Gambia in the past 18 months. However, compliance with the new pre-shipment inspection requirements is crucial to avoid potential regulatory issues.

In the past 18 months, several regulatory changes have impacted Indian pharmaceutical exports to The Gambia:

1. Implementation of Pre-shipment Inspection and Testing: Effective July 1, 2023, the MCA mandated pre-shipment inspections for all pharmaceutical products imported from India. This includes document verification, physical inspection, quality control testing, and the issuance of a CRIA. Quntrol Laboratories Private Limited was appointed to conduct these inspections.

2. Strengthening of Regulatory Framework: The MCA has been enhancing its regulatory framework to ensure the quality and safety of imported medicines. This includes stricter enforcement of GMP standards and more rigorous inspection protocols. These measures aim to align The Gambia's pharmaceutical regulations with international standards.

Importers and exporters must stay informed about these regulatory developments to ensure compliance and facilitate the smooth importation of Acetylsalicylic acid formulations into The Gambia.

As of 2024, Gambia's pharmaceutical market is valued at approximately $34.48 million, with imports from the United States accounting for $16,530. Acetylsalicylic formulations, commonly used for pain relief and cardiovascular health, are integral to this market. The demand is driven by the prevalence of cardiovascular diseases and the country's commitment to universal health coverage. Gambia relies heavily on imports for its pharmaceutical needs, with limited domestic manufacturing capabilities.

Pharmaceutical products classified under HS code 30049099 are subject to a 0% import duty in Gambia. Additionally, these imports are exempt from Value Added Tax (VAT) and other charges, ensuring that essential medicines remain affordable and accessible. There are no Free Trade Agreements (FTAs) between India and Gambia that specifically affect pharmaceutical tariffs, nor are there any anti-dumping duties imposed on these imports.

India is a significant supplier of pharmaceutical products to Gambia, including formulations containing Acetylsalicylic. In 2024, Gambia imported pharmaceutical products worth $16,530 from the United States, indicating a diverse sourcing strategy. While specific data on India's share of Gambia's total Acetylsalicylic imports is not available, India's competitive pricing and established pharmaceutical industry position it as a key player in Gambia's pharmaceutical market.

India is a global leader in the production of generic pharmaceuticals, supplying approximately 20% of the world's generic medicines by volume as of 2024. This extensive manufacturing capability encompasses a wide range of finished dosage forms, including tablets, capsules, syrups, and injections. The country's pharmaceutical sector is supported by over 2,050 WHO Good Manufacturing Practices (GMP)-certified facilities and 752 U.S. FDA-approved manufacturing sites, ensuring high-quality production standards. India's cost-effective production methods, driven by economies of scale and a skilled workforce, make it a preferred source for formulations containing acetylsalicylic acid. The country's robust infrastructure and regulatory compliance provide a reliable supply chain for global markets.

When comparing the export of acetylsalicylic acid formulations, India offers a competitive advantage over China and the European Union (EU) in terms of cost and quality. Indian manufacturers provide finished dosage forms at a lower price point due to efficient production processes and lower labor costs. The quality of Indian pharmaceuticals is upheld by stringent regulatory standards, with numerous facilities approved by international bodies such as the U.S. FDA and WHO. In contrast, while the EU is known for high-quality branded generics, the cost is typically higher, and China's pharmaceutical exports have faced scrutiny over quality concerns. In Gambia, Indian formulations are well-accepted, with a strong track record of supply reliability and regulatory compliance.

India's pharmaceutical industry demonstrates a high level of supply reliability for acetylsalicylic acid formulations. The country's manufacturing capacity is substantial, supported by a large number of WHO GMP-certified and U.S. FDA-approved facilities. Packaging capabilities are advanced, ensuring the integrity of finished dosage forms during transit. There have been no significant supply disruptions reported in recent years, indicating a stable supply chain. Indian manufacturers maintain a strong regulatory compliance record, with instances of non-compliance decreasing over the past decade. Leading manufacturers continue to invest in capacity expansion to meet growing global demand, further enhancing supply reliability.

For buyers in Gambia sourcing acetylsalicylic acid formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts to optimize inventory levels and reduce holding costs.

• Payment Terms: Establish clear payment terms, commonly including letters of credit or advance payments, to build trust and ensure timely transactions.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits and compliance checks, to ensure suppliers meet regulatory standards and quality expectations.

• Regulatory Compliance: Verify that selected suppliers have the necessary certifications (e.g., WHO GMP, U.S. FDA approval) to ensure product quality and facilitate smooth importation processes.

Implementing these strategies will enhance the efficiency and reliability of sourcing acetylsalicylic acid formulations from India.

By adhering to these guidelines, Gambia companies can establish reliable partnerships with Indian manufacturers, ensuring the consistent supply of high-quality acetylsalicylic acid formulations.